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Establishing a clinical service for the
treatment of osteoid osteoma using
magnetic resonance-guided focused
ultrasound: overview and guidelines
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Matthew D. Bucknor5, Fiona Campbell1 and James M. Drake1
Abstract
Recent studies have demonstrated the effectiveness of magnetic resonance-guided focused ultrasound (MRgFUS) in
the treatment of osteoid osteoma (OO), a painful, benign bone tumor. As MRgFUS is a noninvasive and radiation-
free treatment, it stands to replace the current standard of care, percutaneous radiofrequency, or laser thermal
ablation. Within an institution, creation of a clinical OO MRgFUS treatment program would not only provide cutting
edge medical treatment at the current time but would also establish the foundation for an MRgFUS clinical service
to introduce treatments currently under development into clinical practice in the future. The purpose of this
document is to provide information to facilitate creation of a clinical service for MRgFUS treatment of OO by
providing (1) recommendations for the multi-disciplinary management of patients and (2) guidelines regarding
current best practices for MRgFUS treatment. This paper will discuss establishment of a multi-disciplinary clinic,
patient accrual, inclusion/exclusion criteria, diagnosis, preoperative imaging, patient preparation, anesthesia,
treatment planning, targeting and treatment execution, complication avoidance, and patient follow-up to assure
safety and effectiveness.
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Background
Magnetic resonance-guided focused ultrasound is an
emerging option in the treatment of osteoid osteoma.
Early work in this area shows great promise for this non-
invasive and radiation-free treatment modality [1–3]. The
purpose of this document is to provide information to
help facilitate creation of a clinical service for magnetic
resonance-guided focused ultrasound (MRgFUS) treat-
ment of osteoid osteoma (OO) by providing (1) recom-
mendations for the multi-disciplinary management of
patients and (2) guidelines regarding current best practices
for MRgFUS treatment. This paper will discuss establish-
ment of a multi-disciplinary clinic, patient accrual,
inclusion/exclusion criteria, diagnosis, preoperative im-
aging, patient preparation, anesthesia, treatment planning,
targeting and treatment execution, complication avoid-
ance, and patient follow-up to assure safety and
effectiveness.
Osteoid osteoma is a small, painful benign bone lesion
that accounts for 10 % of all bone tumors [4]. OO can
affect male and female patients as young as a few months,
up to the elderly, but predominately affects males between
10 and 35 years of age. These lesions can be painfully dis-
abling, cause neurological dysfunction due to spinal com-
pression [5], be difficult to remove surgically, and may
recur following excision [6]. OOs most commonly occur
not only in the tubular long bones, such as the femur,
tibia, and humerus [6–8], but can also be found in other
bones such as the pelvis and spine [5].
Radiographically, the osteoid-rich nidus and surround-
ing vascular connective tissue typically appears as a central
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sclerotic focus (nidus) surrounded by a lucent area [4]. The
nidus consists of interconnected trabeculae and woven
bone and produces prostaglandin E2 and prostacyclin or
prostaglandin I2 (PGE2 and PGI2), hormones that sensitize
the surrounding tissue to pain [9].
Osteoid osteomas may resolve spontaneously but the
process can take several years. For many patients, the pain
can be severe, with significant impact on health-related
quality of life, including effects on physical, emotional, so-
cial, and role functioning. Early pain management inter-
ventions can reduce pain duration, pain-related disability,
and potentially healthcare expenditures.
Conventional treatment options involve the use of
pain medication, surgical resection, or, more recently,
percutaneous thermal ablation. Conservative manage-
ment is often suboptimal, with analgesics providing
inadequate pain relief and causing side-effects, e.g.,
intolerance from prolonged use of nonsteroidal anti-
inflammatory drugs (NSAIDs). Surgical resection is inva-
sive and associated with a risk of infection, bleeding, and
fracture. Percutaneous treatment methods are less inva-
sive and carry less risk than traditional surgery [6, 7].
However, bleeding, infection, and fracture are still pos-
sible [10]. Additional risks relate to the use of ionizing
radiation for guidance and thermal diffusion. Burns of
the needle tract and skin can result from heat transmit-
ted backwards along an uninsulated coaxial introducer
needle [11].
Minimally invasive, percutaneous thermal ablation
techniques, such as computed tomography (CT)-guided
radiofrequency (RF) ablation, laser ablation [7], and
cryoablation [12] are the current standard-of-care treat-
ment for peripheral bone lesions. However, the possibil-
ity of thermal injury to nontarget tissue is a concern
with thermal ablation procedures. With CT-guided ther-
mal ablation, tissue temperature distribution cannot be
measured directly, placing nearby vital structures (e.g.,
arteries, spinal cord, peripheral nerves) at risk of injury
[13–15]. RF ablation induces temperatures above 90 °C
that are maintained for several minutes in order to ther-
mally coagulate the target [6, 16, 17]. If the temperature
rises above 100 °C, charring blocks RF signal transmis-
sion and further heating of the adjacent tissue is not
possible. During laser ablation, up to 1200 J of energy is
deposited [18, 19] with resultant temperatures exceeding
those during RF. In some cases, the potential for nontar-
get thermal damage necessitates placement of a
temperature sensing needle and the injection of car-
bon dioxide, air, or liquid to act as a heat sink,
thereby increasing the complexity and invasiveness of
the procedure.
Magnetic resonance (MR)-guided laser ablation has
become an attractive alternative to CT-guided ablation
due to the laser’s intrinsic MR compatibility and the
ability to integrate real-time temperature monitoring
into the procedure [18]. However, in order to improve
patient access, these procedures are typically performed
in open, low-field strength magnets that do not provide
adequate signal to noise for accurate thermometry near
low signal tissues, such as bone. Very few centers have
adopted the use of MR guidance for percutaneous
ablation.
A noninvasive treatment modality that provides the
same efficacy as percutaneous ablation, monitors thermal
energy dose during the treatment and reduces risk of
infection and skeletal weakening would be advantageous.
Magnetic resonance-guided high intensity fo-
cused ultrasound
MR-guided focused ultrasound is a noninvasive, out-
patient treatment modality being used to treat uterine fi-
broids and painful bone metastases. Many ongoing
studies are currently underway investigating its use for
cancer and other diseases [20].
MRgFUS is a thermal treatment modality that uses
high-power ultrasonic energy to thermally coagulate tis-
sues in the body. A specially designed transducer is used
to focus a beam of ultrasound energy into a small vol-
ume at a specific target site in the body. The transducer
is placed extracorporeally and is aimed through the skin
to the target without requiring an incision or a sterile
operating environment. The treatment volume of a sin-
gle sonication is small, roughly the size of a grain of rice.
Manufacturers have worked to increase treatment vol-
umes using electronic and mechanical approaches. In
the current generation of machines, electronic steering
allows treatment of up to 5.1 cubic centimeters (cc) and
mechanical transducer motion increases the maximum
treatment volume to 20 cc per sonication in soft tissue.
Due to the sharp focus of the transducer, the ultrasound
beam produces thermal ablation only in the target zone,
which results in cell death when individual cells are ex-
posed to temperatures above 57 °C for a duration of 1 s
or more [21]. Meanwhile, minimal heating of the sur-
rounding tissues (located within the ultrasound beam
but not within the target zone) is harmless since normal
tissue perfusion quickly dissipates the energy. For bone
lesions, since there is no mechanical penetration,
MRgFUS reduces the chance of pathologic fracture and
infection.
MRgFUS heating of bone requires relatively little en-
ergy to achieve thermal ablation compared to soft tissue
treatment, resulting in a wider safety margin. The energy
required for MRgFUS heating of tissue varies due to a
number of factors including the water content, density,
heat capacity, thermal diffusion, and blood flow. Bone
absorbs MRgFUS energy 50 times more readily than soft
tissue does [22, 23]. This improved efficiency in part
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reflects the lower water content and increased acoustic
attenuation of bone. Water has a very high specific heat
capacity, requiring a large amount of energy to increase
temperature. In addition, tissue perfusion and blood flow
act as a heat sink in soft tissues, absorbing and removing
heat energy from the surrounding tissues.
The potential for beam refraction and heat conduction
are among the few limitations to the use of ultrasound
therapy. The area of treatment must be acoustically ac-
cessible, i.e., there is an unobstructed soft tissue window
between the targeted lesion and the MRgFUS transducer.
The presence of a scar or an orthopedic implant could de-
flect the beam resulting in an off-target injury or skin
burn. As with any thermal therapy, thermal diffusion
could result in injury to vital structures (nerves, blood ves-
sels, or the skin surface) in close proximity to the area of
treatment. (See the complications and complication avoid-
ance section below for specific recommendations).
Magnetic resonance imaging (MRI) is used to provide
the anatomical information necessary to safely guide and
focus the ultrasound beam on the target (i.e., the lesion/
nidus, and adjacent periosteum containing the nerves
and vasculature for the nidus) and to perform real-time
multi-planar thermal mapping [24], required to ensure
therapeutic temperatures are produced in the target re-
gion and that surrounding healthy tissue structures are
spared. See Fig. 1. Cell death from coagulative destruc-
tion of the lesion ends prostaglandin production. The
mechanism of posttreatment pain relief, despite residual
lesion perfusion, is unclear [2]. Hypotheses include ther-
mal periosteal denervation and/or thermal ablation of
the nidus’ vasculature that diminishes pressure on sur-
rounding tissues or reduced prostaglandin production.
Treatment of osteoid osteoma with MRgFUS was ini-
tially performed in a small group of adolescent and adult
patients (N = 6) by Napoli et al. [2]. An Insightec ExA-
blate 2100 machine was used to deliver a mean energy
of 866 J (43 W acoustic power for an exposure duration
of 20 s) to achieve thermoablative temperatures of 65 °C
in the soft tissue immediately adjacent to the bone.
These are comparable levels of energy applied during
laser ablation procedures in bone [18, 19]. Following a
single treatment, all of the patients in this study experi-
enced complete pain response by 6-month follow-up,
and there were no device-related serious adverse events
(SAE) reported. Pain scores diminished from 7.9 ± 1.9 on
an 11-point visual analog scale (VAS) to 0.0 ± 0.0. Dur-
ing follow-up imaging (1, 3, 6 months), edema and
hyperemia associated with the osteoid osteoma gradually
decreased in all treated lesions. The vasculature of the
central nidus, however, continued to enhance under
contrast-enhanced T1-weighted MRI in 67 % of patients,
indicating that lesions were likely undertreated, even
though the pain resolved. Previously, total ablation of
the nidus was considered necessary to prevent any re-
current tumor. At 6-month follow-up, no patients re-
quired medication for bone pain and had no further
follow-up treatments for pain recurrence.
A prospective, multi-institutional trial followed 29 pa-
tients undergoing MRgFUS of nonspinal osteoid oste-
oma [1]. All treatments were technically successful using
7 ± 3 sonications (1–12) and 1180 ± 736 J (416–3645)
with an Insightec Exablate 2100 unit. At 1 year, 26/29
patients were pain free, consistent with a 90 % clinical
success rate. The remaining 10 % (three patients) experi-
enced partial pain relief. Two patients underwent subse-
quent radiofrequency ablation and one open surgical
resection. There were no adverse events reported. The
90 % clinical success rate with MRgFUS OO treatment
is equivalent to that of CT-guided radiofrequency abla-
tion [25, 26].
Masciocchi et al. prospectively gathered data on 13 pa-
tients undergoing MRgFUS treatment and compared
them to 30 propensity score-matched patients who
underwent radiofrequency ablation [3]. The methods
were found to be equivalent in regard to pain response
and motor functional recovery.
MRgFUS has also been used to palliate the pain asso-
ciated with metastatic bone cancer [27–31]. The phase
III multi-center study by Hurwitz et al. [27] reported a
positive pain response (decrease in pain score by 2 or
more points by 3 months without an increase in pain
medication) in 64 % (72/112) of patients treated with
Fig. 1 MR of osteoid osteoma. Sagittal T2-w fat saturated MRI image
of a 1-cm cortical osteoid osteoma (white arrowhead) with prominent
bone marrow edema surrounding the left femoral neck lesion. The
location of the intraarticular lesion allows for an unobstructed
treatment window (i.e., no nerves or other vital structures are present
in the ultrasound path)
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MRgFUS that were not candidates for initial or repeated
radiation therapy.
Clinical and technical approach to MRgFUS
treatment
The following sections provide recommendations for es-
tablishing a MRgFUS clinic, patient work-up, and tech-
nical details of treatment.
Team composition and multi-disciplinary clinic
MRgFUS treatment of osteoid osteoma requires the ex-
pertise of several disciplines including interventional
radiology, orthopedic surgery, anesthesia (including a
pain expert), radiography (MRI technologist), physics
(MRgFUS physicist), and nursing. Once a team has been
established, a multi-disciplinary clinic should be formed
to screen potential patients in order to determine which
patients are best suited for MRgFUS and to provide on-
going care and follow-up to previously treated patients.
The multi-disciplinary clinic format enables efficient as-
sessment of patients by interventional radiologists,
orthopedic surgeons, and anesthesiologists (with expert-
ise in both anesthesia and pain management) in a single
visit.
Patient selection
Proper selection of patients is a critical step to the suc-
cessful execution of MRgFUS treatment of OO. In
addition to using good medical judgment when seeking
potential candidates for this therapy, Table 1 describes
suggested inclusion and exclusion criteria. There may be
patients who fall outside of these criteria who are still
appropriate for treatment.
Diagnosis
The clinical presentation and imaging characteristics of
the osteoid osteoma are assessed to help exclude com-
mon differential considerations such as a Brodie’s ab-
scess or rare possibilities such as primary or secondary
malignancy.
When a patient presents with a classic clinical history
(pain, worst at night that responds to NSAIDs) and
pathognomonic imaging findings, treatment can proceed
in the absence of biopsy confirmation [32, 33]. When
the clinical history or the imaging characteristics are in
any way equivocal, a biopsy is recommended. Some op-
erators routinely biopsy all lesions [6, 17]. When biopsy
is undertaken, the access site should be chosen with the
future MRgFUS trajectory in mind. Whenever possible,
the resulting needle track should be perpendicular to the
ultrasound treatment beam path, so that sonication
through scar tissue can be avoided.
Once clinical, imaging, and/or biopsy data is reviewed,
the patient, family, interventional radiologist, and
orthopedic surgeon decide upon the best treatment ap-
proach. Consent to undergo treatment (and take part in
any research study) is obtained from older patients and/
or parents. Assent should be sought in younger patients.
Determination of best treatment modality
Although this document focuses on guidelines and best
practices for treatment of OO using MRgFUS, this mo-
dality may not be the best choice for all patients, even in
light of the inclusion/exclusion criteria above. MRgFUS
is a very powerful device and is changing the way some
patients with OO are treated; it is still a developing re-
search technique that has both technical limitations as
well as an associated learning curve. Experience brings
the ability to accurately predict when difficult lesions
and complex approaches will help enable good results.
During the initial development phase of an MRgFUS
program, consultation with more experienced operators
regarding patient eligibility, targeting, and complication
avoidance when targeting complex lesions is extremely
important. For the foreseeable future, surgical and/or
Table 1 General inclusion and exclusion criteria for osteoid
osteoma MRgFUS treatment
Inclusion criteria
• Age ≥5 years
• Subject able to give informed consent or subject assents with
informed consent from parent or guardian
• Weight <140 kg (requirement to fit safely on top of the MRgFUS table
and inside the MR magnet)
• Definitive radiographic and clinical presentation of an osteoid osteoma
o OR biopsy proven osteoid osteoma when clinical or imaging
findings are inconclusive
• Pain specifically at the site of interest (target lesion)
• Pain intensity (for the target lesion) in the moderate to severe range
as measured by age-appropriate validated pain assessment tools.
• Target lesion is uncomplicated (no fracture/spinal cord compression/
cauda equina syndrome/soft tissue component)
• Target lesion maximum dimension ≤3 cm (otherwise lesion may not
be an OO)
• Target lesion visible by noncontrast MRI
• Target lesion accessible for MRgFUS procedure
• MRgFUS treatment date ≥2 weeks from most recent surgical/radiologic
treatment of osteoid osteoma
Exclusion criteria
• Unable to characterize pain specifically at the site of interest (target lesion)
• Pregnant female
• Target lesion is complicated (presence of one of fracture/soft tissue
component).
• Target lesion <1 cm away from the skin, neurovascular bundles, bowel,
hollow viscera, or regions of cartilage/ bone growth plate
• Target lesion located in the skull and spine (excluding sacrum)
• Inability to position area of interest on the MRgFUS transducer
• Scar along proposed MRgFUS beam path or unable to exclude scar from
path
• Orthopedic implant along proposed MRgFUS beam path or at site of target
lesion
• Serious cardiovascular, neurological, renal, or hematological chronic disease
• Active infection
• Contraindication to deep sedation/general anesthesia or MRI
• Contraindication to gadolinium (nursing mothers, renal failure, etc.) is a
relative contraindication to the procedure. MRgFUS can still be performed
but perfusion information would not be obtained.
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percutaneous treatment will still be required for lesions
in the spine, acoustically inaccessible locations, and
MRgFUS treatment failures. The responsible physician
should meet with the patient to discuss all potential
options for treatment outlining the risks and benefits of
each.
Pain evaluation
The primary goal of osteoid osteoma treatment is pain
relief. Easily administered validated age-appropriate
measures of pain intensity must be used. The Faces Pain
Scale—Revised (FPS-R) is recommended for use in chil-
dren aged 4–17 years; FPS-R = 4–6 indicates moderate
pain and greater than 6 severe pain [34]. The numeric
rating scale (NRS) is recommended for use in adults and
children >8 years; NRS = 4–6 indicates moderate pain
and 7–10 severe pain [35]. The Brief Pain Inventory
(BPI) is another measure of pain and pain-related
disability commonly used in adults [36]. The Pediatric
Initiative on Methods, Management, and Pain Assess-
ment in Clinical Trials (PEDIMMPACT) report [37] out-
lines eight broad categories for reporting outcomes of
pediatric pain clinical trials: pain intensity, global satis-
faction with treatment, symptoms and adverse events,
physical recovery/functioning (acute/chronic), emotional
response/functioning (acute/chronic), role functioning,
sleep, and economic factors. For future research studies,
it is recommended that validated measures to capture
these outcomes should also be used.
Preoperative imaging and patient workup
As previously discussed, results of any recent existing
diagnostic imaging tests should be examined to determine
eligibility for MRgFUS treatment. All patients should
undergo an appropriate imaging work-up to allow for
diagnosis of osteoid osteoma as determined by the inter-
ventional radiologist. A standardized set of 3D MR images
(see Fig. 1) will then be obtained to use for MRgFUS plan-
ning. A prior CT scan is often required to assess lesion
characteristics and position.
Prior to the MRgFUS procedure, baseline blood work
(complete blood count, electrolytes, creatinine) and a
planning MRI are obtained. If a recent MRI is available,
it can be used for treatment planning (at the discretion
of the radiologist). The target lesion is assessed for any
interval change (from the original imaging), and accessi-
bility of the lesion is verified.
Patient preparation and treatment planning
Before beginning the treatment, the following steps are
performed:
 Appropriate quality assurance and safety testing of
MRI and MRgFUS equipment.
 The area of interest should be shaved and a commercial
depilatory cream (e.g., Nair, Veet,) may be used to
further clean the skin surface. Sticky tape is used to pick
up any loose hairs after shaving. The skin can be cleaned
with chlorhexidine (to remove any skin oil or residue
that could affect beam penetration) and allowed to dry.
 The treatment area and the corresponding skin
surface for ultrasound beam entry should be
landmarked.
 The patient is placed on the MRgFUS table with
appropriate padding to avoid pressure-related injury
and prevent movement during the procedure. The
area of interest is positioned in the center of the
ultrasound transducer.
 An aqueous interface (gel pad, circulating disc,
water bath, etc.) will be used to couple the skin
surface to the MRgFUS transducer window. All
water should be degassed as per manufacturer’s
specifications.
 MRI-compatible patient monitoring devices
(oximetry, pulse, ECG, body temperature, etc.) are
placed and enabled.
 As patients must remain still during the painful
MRgFUS procedure, general anesthetic, deep
sedation, local nerve blocks, and/or spinal anesthesia
is used. The patient should be positioned with the
area of interest on the gel pad (see Fig. 2) and then
appropriately anesthetized/sedated.1 Any MRI
imaging coils should be attached and secured at this
time.
Fig. 2 Focused ultrasound therapy setup. Axial T1-w MRI showing
osteoid osteoma of right lateral femoral diaphysis (white arrowhead)
placed onto gel pad (GP) overlying ultrasound transducer (FUST)
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 Survey imaging and a bubble detection scan, a
balanced fast field (gradient) echo sequence that is
sensitive to the susceptibility artifact created at air-
water interfaces, are performed (see Fig. 3). Air
trapped between the transducer, gel pad, or patient
could absorb or scatter the ultrasound energy and
lead to unpredictable heating in the near field. If
there is a bubble(s), then the patient will need to be
moved off the pad, the bubble removed, the patient
repositioned, and the imaging repeated.
 3D T1- and/or T2-weighted sequences of the target
bone/lesion are then acquired. These image se-
quences should have good bone/soft tissue/marrow
contrast as well as a large enough field of view to
observe the bone surface and skin entry point. If the
lesion does not lie within the possible MRgFUS
treatment volume, the patient is repositioned and
the imaging repeated.
 This imaging sequence is then imported into the
treatment planning software on the MRgFUS
workstation, so that overall position of the lesion
with respect to the MRgFUS device can be assessed,
and the optimal acoustic window can be determined.
See Fig. 4.
Targeting, treatment execution, and monitoring
Once all preoperative imaging has been performed and
pushed to the treatment planning workstation, targeting
of the OO lesion and treatment execution can begin.
The following are recommended steps to execute this
process:
 Positioning of the treatment cell(s) depends on the
size and location of the OO and the type of
equipment being used. The ultrasound focus should
be placed either on the cortical surface or deep to
the target lesion (e.g., between the subcortical and
the far field cortex). With MRgFUS treatment of
bone, it is recommended that small treatment cells
are selected. Large treatment cells with electronic
steering will create instances where the incident
ultrasound beam is oblique to the bone surface and
will be reflected or refracted to unwanted locations.
An orthogonal beam trajectory will minimize the
potential for off-target heating due to beam reflection/
refraction.
 Depending on the size of the OO, as little as one
treatment cell may be required. However, a small
cluster of treatment cells placed radially around a
central target maximizes energy deposition to the
nidus. See Figs. 4 and 5.
 Once the treatment plan is defined, a MR thermal
map sequence is prescribed. The imaging plane(s)
should include the MRgFUS treatment cell as well
as a near-field MRI image so that the temperature at
the muscle/fat interface can be measured, which is
indicative of the skin surface temperature. A far field
image is not required as all the energy will be
absorbed by the bone and the wave energy will not
continue past the target (see Fig. 4).
 On both the InSightec ExAblate and Philips
Sonalleve systems, an automated sequence
completes a minimum of two pre-sonication phase
image sequences (up to 3 s each), which are used to
perform future subtractions for the thermal imaging
sequence. To best optimize thermometry image
quality, some operators suggest running the MR
thermal mapping sequence for a few minutes with-
out sonication to gauge the signal-to-noise ratio
(SNR) and determine if there is any periodic shift in
the image due to respiratory motion. Adjustments to
the sequence (voxel size, FOV, echo time) can then
be made until the background noise is acceptable.
 A test shot of 5–15 W for 10 s is performed to
determine whether the acoustic energy is getting to
the target bone surface or if there is undesired
heating in the near field.
 Sequential treatments of 40–60 W for 20–30 s
(800–1800 J) should then be performed. It is best
practice to start at lower power values and
progressively increase the power until the
temperature measured at the target bone surface
meets or exceeds 65 °C. See Figs. 4 and 5.
Fig. 3 Bubble test. A coronal skin bubble scan (balanced fast
gradient echo sequence) showing a 1-cm air bubble trapped be-
tween the patient and the acoustic coupling pad. If this bubble is
not removed from the beam path, a skin burn could occur due to
the treatment
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 The treatment session ends when all cell clusters
have achieved the desired target temperature. If at
any time during the treatment, near-field heating or
any other unexpected behavior is observed, then the
current exposure should be aborted and the treatment
plan should be reevaluated. If there is concern that
continued exposures will lead to an adverse event,
then treatment should be aborted.
 Once the treatment concludes (or is aborted), pre-
and post-T1W gadolinium sequences are acquired.
Voxel-by-voxel subtraction is performed to assess
posttreatment perfusion.
 The patient is removed from the MRI and recovered
from anesthesia or sedation.
 Visual inspection of the skin surface is performed to
assess for the presence of treatment-related skin burns.
 If any nerves were located near the treatment zone,
corresponding motor and/or sensory evaluation
should be performed.
 Recovered patients are either discharged or admitted
for follow-up care at the discretion of the
anesthesiologist and interventional radiologist.
 Patients are provided with emergency contact
information and discharge instructions.
 Guidelines for ambulation following MRgFUS
treatment of weight-bearing bones have not been
established. Ultrasound therapy has been shown to
result in bone weakening in some in vivo studies
[38–40].
Complications and complication avoidance
Although MRgFUS is a noninvasive modality for treat-
ment of OO and other diseases, there are many consid-
erations required to ensure patient safety and help avoid
treatment complications:
 Preparation of the skin: One of the most effective
ways to minimize a skin burn or other skin irritation
Fig. 4 MRgFUS treatment planning. MRgFUS treatment of tibial osteoid osteoma, showing the InSightec ExAblate user interface. Subtracted
phase images (top panel) are used to calculate temperature, with temperatures reaching 65 °C at the target (bottom right panel). A magnified EPI
magnitude image (bottom left panel) shows the targeting. The position of the single focus (green plus sign) is adjusted such that the beam path
(blue hourglass) intersects the bone (green line), creating a sonication spot (green circle). Thermal dose (green) is present at the bone surface. Note
that the focal zone has been placed deep to the bone cortex in order to heat a larger bone surface area, and the beam has been oriented to
avoid the neurovascular bundle
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is to properly shave and depilate the skin surface as
mentioned above. When performed in conjunction
with the use of degassed water and/or ultrasound gel
for acoustic coupling of the patient to the MRgFUS
system, the risk of trapped air between the patient
and transducer is reduced. An MRI image of the
coupling between the patient and the gel pad should
be acquired to assess coupling before treatment. A
balanced gradient echo image works well in this
situation as air bubbles create a small susceptibility
artifact. If air bubbles are discovered during this stage,
the patient must be repositioned and additional
degassed water should be applied to the gel pad until
no bubbles are visible in the interface.
 Location of the target: Since bone tissue absorbs
ultrasound readily and the absorption of that energy
is predominately converted to heat, it is natural that
bone tissue heats up more than the surrounding soft
tissues. Great care must be used to ensure that a
safe margin (generally considered 1 cm) of soft
tissue is around the bone target before reaching the
skin surface or other sensitive tissue such as the
major nerves or blood vessels. For example, an
osteoid osteoma located in the anterior tibia may be
a poor choice for this modality as there is no
mechanism for heat dissipation since there is little
tissue perfusion if the skin is immediately adjacent
to the bone.
 Acoustic access to the target: The MRgFUS
transducer can analogously be compared to an optical
lens, as it has a focal length and beam width. As the
energy converges to the focus, the beam width narrows
but may be quite wide at the entrance point into the
body. Any object in the beam path that could reflect
ultrasound energy, such as a gas-filled viscus or bone,
needs to be outside this beam path or refocusing and
off-target heating may occur. This can best be avoided
by using large field of view, three plane planning images
so that the entire beam path can be inspected before
treatment.
Patient follow-up and postoperative imaging
The patient should be monitored for both short- and long-
term effects of treatment. The initial clinical follow-up
Fig. 5 Thermography during osteoid osteoma treatment. Planned treatment cells for the osteoid osteoma from Fig. 1 shown in a coronal and b
axial MRI views on a Philips Sonalleve platform. (User interface not shown). Seven 4-mm treatment cells were arranged in a circular cluster in the
coronal plane to cover the entire 1-cm lesion. Due to electronic beam steering on the Sonalleve machine, the focal zone was positioned at the
bone surface in the osteoid osteoma. c Sagittal and d axial images demonstrate thermal maps from a 50-W (1000 J) treatment sonication. This
exposure produced a maximum temperature above 60 °C at the bone surface. A small region (approximately 1 × 4 mm) adjacent to the osteoid
osteoma reached sufficient temperatures to achieve a thermal dose of 240EM@43 °C, causing necrosis.
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appointment should be scheduled within the first 2 weeks
and further follow-up as required for up to 6 months. As
MRgFUS is a new treatment modality, follow-up MRI im-
aging can be considered after 3–6 months.
Treatment failure and retreatment
There may be instances where the MRgFUS treatment
of the OO does not work as effectively as expected or
fails to have a therapeutic benefit. In those instances, it
is important for the team to reassess what factors con-
tributed to the less than ideal results. The cause of many
treatment failures can usually be reduced to the follow-
ing issues: inappropriate selection of patient, inadequate
acoustic coupling, poor targeting of the lesion, and inad-
equate selection of treatment power and duration. These
issues are summarized below:
 Inappropriate selection of patient: This can be a
complicated issue as the thought of offering this
noninvasive treatment to all patients suffering from
OO can be alluring. However, restraint must be
exercised to know when a patient can be better
treated by another modality. Adherence to the
inclusion and exclusion criteria listed above is the
best way to ensure that patients are selected
appropriately.
 Inadequate acoustic coupling: This is a two-part
technical issue of MRgFUS treatment that can be
avoided with care and expertise, as mentioned
above.
 Poor targeting of the lesion: Osteoid osteomas
generally occur in three distinct locations in the
bone—subperiosteal, cortical, or intramedullary. Of
these, subperiosteal are generally considered the
easiest to treat, while intramedullary are the most
challenging due to the thickness of the overlying
bone. With subperiosteal lesions, a single small
treatment cell can be placed directly on the target.
For intramedullary lesions, the acoustic wave does
not actually reach the target, as it is absorbed in the
surface of the bone. For these treatments, it is the
conduction of heat through the bone that leads to
heating of the target. As such, the optimal position
of the focus may be beyond the lesion so that a
larger surface of the bone can be heated, creating a
hemispherical heating aperture that converges on
the lesion.
 Inadequate selection of treatment power and
duration: The distinction between subperiosteal,
cortical, and intramedullary lesions should also be
considered in the selection of treatment power and
duration. With subperiosteal lesions, a single exposure
directly on the target with a relatively low acoustic
power of 40–60 W for 20–30 s (800–1800 J) can
successfully destroy the lesion. Intramedullary lesions
will often require several exposures upwards of 80 W
to maintain a high temperature at the bone surface,
allowing time for the heat to conduct inwards into the
lesion. The individual exposure times should still be
kept < 40 s to allow the soft tissue to cool but since
bone retains its heat longer, repeat exposures enable
sustained temperature in the bone.
Future directions
This document has outlined a series of guidelines and
best practices for the thermal ablation and treatment of
osteoid osteoma using MRgFUS in order to help new
centers interested in this treatment approach. In
addition, this could also be viewed as a first step to help
organize and consolidate the clinical and research efforts
of these centers to collaboratively work towards future
advances in clinical MRgFUS therapies. Examples of po-
tential future developments include:
 Modeling: A common feature of energy-based
therapy modalities, such as radiation therapy, is the
ability to model the treatment procedure and the
response of tissue to treatment before the patient is
actually treated. This is an emerging trend in
MRgFUS treatment and active research is directed
at modeling the thermal effects in and around the
bone during MRgFUS treatment and estimating the
response of tissue to the thermal dose. As clinical
data is acquired and as these models become more
accurate, a repository of clinical data could be
retrospectively analyzed to validate these models
using real treatment temperature data.
 Treatment registry: As more centers adopt this
treatment approach, it will be crucial to develop
patient registries to more comprehensively evaluate
patient reported outcomes and facilitate clinical
trials. The generation of larger data sets will help to
train/test modeling techniques and create a
centralized repository for all data when the
community decides that dissemination of the results
via peer-reviewed publication as appropriate. This
data can also be used to facilitate comparisons of
MRgFUS with standard treatment. For example, an
MRgFUS OO treatment registry is being concurrently
developed with a percutaneous OO treatment registry
organized by the Society of Pediatric Interventional
Radiology (SPIR).
 Clinical trials comparing MRgFUS to conventional
thermal treatments: For MRgFUS treatment of OO
to become the new standard of care, it will need to
be compared to the current standard, which is
radiofrequency or laser ablation. Data from the
registry will facilitate design of such a trial in terms
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of patient numbers and outcomes and should
enhance funding success rates by demonstration of a
track record of collaboration.
 Treatment of OO of the spine: Another common
location for OO is the spine, which represents one
of the most difficult treatment locations using any
heat-based modality, especially HIFU. Currently, the
standard-of-care is percutaneous RF or laser fiber
ablation since the volume of ablation and heat
spread can be more confined. However, this involves
guiding a bone biopsy needle into the spine. With
increased experience in treating bone lesions and
development of reliable thermal heading prediction
models, certain areas of the spine may become
viable targets.
 Progression of equipment design: The MR and
MRgFUS equipment currently available was
designed primarily for the treatment of uterine
fibroids. As bone lesions can occur anywhere in the
body, the MRgFUS community should work with
industry partners to create equipment that is more
adaptable to a wide range of patient positioning
requirements.
Conclusions
MRgFUS treatment of OO shows great promise and has
numerous advantages over current therapies. This paper
has provided recommendations for establishing a clinical
MRgFUS treatment program and an overview of the
current treatment strategy. Given the positive results of
initial pilot studies, investigators should strive to organize
larger multi-center studies and eventually a phase III trial
comparing outcomes between MRgFUS and radiofre-
quency/laser ablation. Establishing MRgFUS as an effect-
ive treatment for osteoid osteoma will also help support
investigation into the treatment of other bone lesions such
as osteoblastoma, aneurysmal bone cyst, and eosinophilic
granuloma.
Endnotes
1Younger or less cooperative patients may require
sedation/general anesthesia prior to positioning.
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